• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
LeadershipCoronavirus

Pfizer is investing in a ‘surveillance network’ to detect coronavirus variants

By
Beth Kowitt
Beth Kowitt
Down Arrow Button Icon
By
Beth Kowitt
Beth Kowitt
Down Arrow Button Icon
January 28, 2021, 8:30 PM ET

Pfizer is investing in a “very comprehensive surveillance network” in order to detect coronavirus variants, says CEO Albert Bourla.

“Any variant that comes out, we take it and we test it against our vaccines,” says Bourla, who spoke today as part of a Fortune virtual event tied to the annual Davos meeting of the World Economic Forum.

When it comes to the variant of the coronavirus first detected in South Africa, studies indicate that the Pfizer vaccine produces fewer antibodies against this version of the virus. Bourla, however, said the company does “not believe that affects the performance of the vaccine against those variants.”

But, he added, it is likely that there will at some point be a variant that escapes the protection of the Pfizer vaccine. He says the company’s surveillance network would allow Pfizer to rapidly identify variants and then create a booster vaccine to fight them. He equated these boosters with having the operating system on your smartphone updated.

Bourla said he expects we will soon start to see some “real results” from the vaccination efforts and pointed to Israel as an example of a country that is making progress. The challenge right now is delivering the vaccine to as many people as possible, which he says is hamstrung by the need to coordinate different governments and national plans. But overall, he said, “I’m optimistic about our ability to control this pandemic.”

Larry Merlo, the CEO of CVS Health, also addressed the group, saying, “there’s optimism that by the time we get to the spring timeframe, there is now ample supply” of the vaccine. He said by June and July, hopefully, “we’re reaching that point of a large number of Americans vaccinated where we can begin to talk about herd immunity.”

Bourla said that one of the lessons of the pandemic is “the power of science, particularly in the hands of the private sector.” He said if someone had told him at the beginning of the pandemic that the company would develop a vaccine within nine months that’s 95% effective, he would not have believed it. He stressed the importance of maintaining a “vibrant science-based, innovation-based industry.”

About the Author
By Beth Kowitt
LinkedIn iconTwitter icon
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.